Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Blueprint Medicines Corp (BPMC)
|
Add to portfolio |
|
|
|
| Price: |
$110.08
| | Metrics |
| OS: |
59.7
|
M
| |
-94
|
% ROE
|
| Market cap: |
$6.57
|
B
| |
-80
|
% ROIC
|
|
Net cash:
|
$776
|
M
| |
$12.99
|
per share
|
|
EV:
|
$5.8
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($690)
|
M
| |
|
|
|
EBIT
|
($697)
|
M
| |
|
|
| EPS |
($11.91)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 180.1 | 793.7 | 66.5 | 44.5 | 21.4 | 27.8 | 11.4 | 0.0 |
| Revenue growth | -77.3% | 1093.4% | 49.4% | 107.8% | -22.9% | 143.6% | | |
| Cost of goods sold | 17.9 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 162.1 | 793.3 | 66.5 | 44.5 | 21.4 | 27.8 | 11.4 | 0.0 |
| Gross margin | 90.0% | 99.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Selling, general and administrative | 195.3 | 157.7 | 96.4 | 47.9 | | | | |
| Research and development | 601.0 | 326.9 | 331.5 | 243.6 | 144.7 | 81.1 | 48.6 | 31.8 |
| General and administrative | | | | | 28.0 | 19.2 | 14.5 | 7.9 |
| EBIT | -642.0 | 308.7 | -361.3 | -247.0 | -151.2 | -72.6 | -51.6 | -39.7 |
| EBIT margin | -356.5% | 38.9% | -543.2% | -554.9% | -705.9% | -261.3% | -453.0% | |
| Pre-tax income | -641.1 | 314.9 | -347.7 | -236.6 | -148.1 | -72.5 | -52.8 | -40.3 |
| Income taxes | 3.0 | 1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -644.1 | 313.9 | -347.7 | -236.6 | -148.1 | -72.5 | -55.9 | -46.1 |
| Net margin | -357.7% | 39.5% | -522.8% | -531.5% | -691.3% | -261.0% | -490.5% | |
| |
| Diluted EPS | ($11.01) | $5.59 | ($7.27) | ($5.39) | ($3.92) | ($2.64) | ($3.07) | ($32.41) |
| Shares outstanding (diluted) | 58.5 | 56.2 | 47.8 | 43.9 | 37.8 | 27.5 | 18.2 | 1.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|